Recent Invokana Lawsuit News Raises Concern Over Ketoacidosis Side Effects Linked To Drug

March 09, 2016 – – TheProductLawyers.com announces recent reports of 101 patient cases of diabetic ketoacidosis which have been linked to their use of Invokana and other SGLT2 inhibitor drugs according to a safety warning issued by the European Medicines Agency. There are multiple brands of SGLT2 inhibitors available to consumers at this time, however, Invokana was the first of the new-generation diabetes medications to be released.

SGLT2 is an abbreviation for sodium-glucose cotransporter-2 drugs. The drugs in this category work by controlling blood glucose (sugar) levels for diabetic patients by removing excess sugar from the body through urination. EMA’s most recent report also notes that over 500,000 diabetic patients have now used SGLT2 class inhibitors since March, 2013 when they were initially released to market.

Ketoacidosis is a potentially life-threatening condition in which the body produces too many ketones, causing the bloodstream to contain too much toxic acid. The condition can appear in as little as 24 hours and, if it remains undiagnosed, can cause patients to enter a coma or die.

The EMA’s warning stated, “Although diabetic ketoacidosis is usually accompanied by high blood sugar levels, in a number of these reports blood sugar levels were only moderately increased. These uncharacteristic blood levels could delay diagnosis and treatment.” Because of this trouble with diagnosing such a serious and even deadly ketoacidosis condition, many medical professionals are requesting that those currently using SGLT2 inhibitors remain extra aware of any indicators that the body may be developing ketoacidosis.

According to the U.S. Food and Drug Administration (FDA) they have also received reports of ketoacidosis cases which were connected to patient’s use of several SGLT2 inhibitor drugs within only their first year on the market. SGLT2 drugs mentioned in the FDA reports include: Invokana, Invokamet, Glyxambi, Farxiga, Jardiance, and Xigduo XR.

The attorneys of Banville Law, who sponsor online resource website TheProductLawyers.com, understand the seriousness of ketoacidosis conditions, and they understand how important it is for diabetes patients to obtain safe and effective treatments. They are now working to help ensure that everyone who took SGLT2 class drugs and who suffered from health problems which they attribute to the drugs will be provided the important opportunity to evaluate their legal rights in full. Banville Law is currently offering complimentary legal consultations to affected parties at this time. These individuals may be entitled to significant compensation.

To obtain additional information on Invokana, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008587